| 1.38 0.03 (2.22%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.97  |
1-year : | 2.25 |
| Resists | First : | 1.69 |
Second : | 1.92 |
| Pivot price | 1.45 |
|||
| Supports | First : | 1.3 |
Second : | 1.08 |
| MAs | MA(5) : | 1.4 |
MA(20) : | 1.5 |
| MA(100) : | 3.62 |
MA(250) : | 3.49 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.6 |
D(3) : | 14.3 |
| RSI | RSI(14): 34.5 |
|||
| 52-week | High : | 7.8 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PEPG ] has closed above bottom band by 16.1%. Bollinger Bands are 88.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.4 - 1.4 | 1.4 - 1.41 |
| Low: | 1.29 - 1.3 | 1.3 - 1.31 |
| Close: | 1.37 - 1.38 | 1.38 - 1.39 |
PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.
Tue, 26 May 2026
PepGen (NASDAQ: PEPG) CTO executes mandatory sell-to-cover RSU shares - Stock Titan
Thu, 21 May 2026
PepGen (NASDAQ: PEPG) details DM1 trial data and cash runway outlook - Stock Titan
Thu, 21 May 2026
[EFFECT] PepGen Inc. SEC Filing - Stock Titan
Wed, 20 May 2026
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo! Finance Canada
Sun, 17 May 2026
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 90.1 (%) |
| Shares Short | 3,460 (K) |
| Shares Short P.Month | 3,570 (K) |
| EPS | -1.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.8 % |
| Return on Equity (ttm) | -68.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.95 |
| PEG Ratio | 0 |
| Price to Book value | 0.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|